查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158749

米哚妥林原料藥市場：全球市場預測，2026-2032年

Midostaurin API Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，米哚妥林原料藥(API) 的市場規模將成長至 5.2542 億美元，複合年成長率為 11.26%。

主要市場統計數據
基準年 2025 2.4888億美元
預計年份：2026年 2.7774億美元
預測年份 2032 5.2542億美元
複合年成長率 (%) 11.26%

原料藥：執行摘要與策略背景

米哚妥林類原料藥（API）是特定血液腫瘤領域藥物生產的基礎。其策略環境受到嚴格的品質要求、專業化的生產能力、監管、供應連續性以及從研發到商業化生產過程中可靠的分析控制等因素的影響。產業相關人員必須評估原料藥在其整個生命週期中的技術可行性、文件品質、合規性和穩定性。

監管的日益複雜化和供應鏈的韌性正在改變米哚妥林類原料藥的模式。

隨著對雜質控制、製程驗證、資料完整性、可追溯性和變更管理的要求日益嚴格，產業格局正在轉變。買家在評估供應商時，不僅關注名義上的供貨能力，還越來越重視生產一致性、審計準備、批次放行支援、緊急時應對計畫以及技術轉移管理能力。對醫藥供應鏈日益嚴格的審查也推動了雙重採購策略、強化庫存管理以及原料藥生產商、製劑生產商和法規遵從團隊之間更緊密的合作。

人工智慧（AI）增強了品質、開發和供應方面的決策能力。

人工智慧 (AI) 可透過識別製程偏差、協助監測分析趨勢、確定實驗室檢測優先順序以及改進需求和庫存計劃，為米哚妥林原料藥的整個價值鏈做出貢獻。機器學習工具還可用於生產路線的比較分析、程式參數最佳化、文件審查和預測性維護。其價值取決於具有代表性的數據、檢驗的工作流程、人工監督、網路安全以及對適用電腦系統和數據完整性要求的遵守情況。人工智慧應作為合格專家的補充，而非取代必要的科學判斷。

區域洞察：不同的法規和製造業優先事項

在北美，監管合規、供應鏈安全和完善的品質系統至關重要；而在拉丁美洲，進口可靠性、註冊要求和本地分銷協調則更為關鍵。歐洲的特徵是，各個相互關聯的市場都對品質、環境和文件有著嚴格的要求。在中東，可靠的供應管道、合格的採購來源和策略供應鏈的連續性日益受到重視。非洲在基礎設施、物流和監管能力方面存在差異，這可能會影響採購的執行。亞太地區擁有大規模的製藥生產能力，但各國標準不盡相同，技術能力不斷提升，並且持續關注合格、智慧財產權保護和具有韌性的跨境供應鏈。

集團洞察：貿易、監管和策略協同影響採購

在東協市場，必須仔細考慮不同的監管路徑、物流網路和生產能力。金磚國家成員國的產業基礎和政策環境各不相同，因此供應商合格和跨境協調至關重要。歐盟受益於監管協調，同時在國家層級維持營運的考量。在七國集團市場，普遍對合規性、品質和藥品安全監測有較高的要求。海灣合作理事會成員國優先考慮可靠的採購、區域物流和醫療衛生安全，而北約成員國則可能更加關注戰略重要藥品的韌性、可靠的供應鏈網路和業務永續營運計劃。

國家概況：各國的能力和合規要求各不相同。

澳洲兼具成熟的監管要求和地域性供應鏈考量。巴西和墨西哥則需要格外關注註冊、進口程序和本地分銷執行。加拿大和美國強調健全的品質系統、完善的文件記錄和供應鏈的連續性。中國和印度擁有大規模的藥品生產能力，但需要仔細評估製造地的合規性、檢查準備、智慧財產權保護和資料完整性。法國、德國、義大利、西班牙和英國在極其嚴格的歐洲或符合歐洲標準的法規環境下運營，注重品質、可追溯性和可靠的供應。日本和韓國優先考慮高度的生產規範、嚴格的監管和一致的技術文件。俄羅斯則涉及市場准入、貿易限制、物流和供應鏈風險等其他方面的考量。

針對米哚妥林原料藥產業領導者的策略措施。

行業領導者應透過技術審核、雜質和分析方法審查、流程驗證證據、變更管理記錄以及書面業務永續營運計劃來評估供應商合格。在可行的情況下，確保擁有多個合格供應商可以降低集中風險，而嚴格的庫存管理政策應反映前置作業時間、出貨前測試和監管要求。企業也應加強技術轉移管治，儘早協調品管和採購團隊，並隨時了解各國的具體監管資訊。在實施人工智慧時，應從可管理且可審計的用例入手，例如偏差優先排序、實驗室數據趨勢分析和文件支持，並以檢驗、存取控制和明確的問責制為基礎。

調查方法：基於證據評估米哚妥林原料藥(API) 的現況。

本執行摘要採用定性且基於證據的框架，重點關注與米哚妥林原料藥) 相關的技術、監管、運作和地理因素。評估內容涵蓋生產能力、品質預期、市場准入條件、物流、供應彈性以及數位轉型，並有系統地整合了跨區域、跨國企業集團和各國的洞察。本摘要有意排除了市場估算和預測、市場規模計算、市場佔有率、預測以及未經證實的公司特定聲明。結論應根據最新的監管公告、官方標準、供應商審核結果、技術文件以及適用的貿易和採購要求檢驗。

結論：品質保證和健全的採購體係是取得競爭優勢的關鍵。

米哚妥林原料藥的策略制定，如今不僅取決於供應情況，還取決於可靠的品質、合規性、分析控制和韌性。雖然需要根據地區和國家的差異進行具體實施，但人工智慧若管理得當，可以為流程監控和營運決策提供切實可行的支援。那些整合嚴格的供應商認證、業務永續營運計劃、合規的數位化工具和跨職能管治的行業領導者，將更有能力應對技術複雜性並確保可靠的供應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 米哚妥原料藥市場：依適應症分類

  • 急性骨髓性白血病
  • 系統性肥大細胞增生症

第8章 米哚妥林原料藥市場：依治療階段分類

  • 一線治療
  • 第二線及以後

第9章 米哚妥林原料藥市場：依劑型分類

  • 靜脈
  • 口服
    • 膠囊
    • 藥片

第10章：米哚妥林原料藥市場：依患者類型分類

  • 成人
  • 兒童

第11章 米哚妥林原料藥市場：依通路分類

  • 醫院藥房
  • 零售藥房

第12章 米哚妥林原料藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 米哚妥林原料藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 米哚妥林原料藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Apino Pharma Co., Ltd.
  • Aurobindo Pharma Limited
  • Chunghwa Chemical Synthesis & Biotech Co., Ltd.
  • Cipla Limited
  • Concord Biotech Limited
  • Dr. Reddy's Laboratories Limited
  • Hetero Labs Limited
  • Jubilant Life Sciences Limited
  • MSN Laboratories Private Limited
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Procos SpA
  • SETV Global Private Limited
  • Sun Pharmaceutical Industries Limited
  • TAPI Hungary Industries Kft.
  • Teva Pharmaceutical Works Private Limited
  • Viatris Inc.
  • Zaklady Farmaceutyczne Polpharma SA
  • Zydus Lifesciences Limited

第17章 主要專家

Product Code: MRR-4654A89DBBC9

The Midostaurin API Market is projected to grow by USD 525.42 million at a CAGR of 11.26% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 248.88 million
Estimated Year [2026] USD 277.74 million
Forecast Year [2032] USD 525.42 million
CAGR (%) 11.26%

Midostaurin API: Executive Summary and Strategic Context

Midostaurin active pharmaceutical ingredient (API) supports the manufacture of medicines used in defined hematologic oncology settings. The strategic context is shaped by stringent quality requirements, specialized production capabilities, regulatory oversight, supply continuity, and the need for reliable analytical control across development and commercial manufacturing. Industry participants must evaluate technical feasibility, documentation quality, compliance readiness, and resilience throughout the API lifecycle.

Regulatory Complexity and Supply Resilience Are Reshaping Midostaurin API

The landscape is being transformed by tighter expectations for impurity control, process validation, data integrity, traceability, and change management. Buyers increasingly assess suppliers beyond nominal availability, examining manufacturing consistency, audit readiness, batch-release support, contingency planning, and the ability to manage technology transfers. Greater scrutiny of pharmaceutical supply chains is also encouraging dual-sourcing strategies, stronger inventory governance, and closer coordination between API producers, drug-product manufacturers, and regulatory teams.

Artificial Intelligence Strengthens Quality, Development, and Supply Decisions

Artificial intelligence can contribute across the midostaurin API value chain by identifying process deviations, supporting analytical-trend monitoring, prioritizing laboratory investigations, and improving demand and inventory planning. Machine-learning tools may also assist route-development comparisons, process-parameter optimization, documentation review, and predictive maintenance. Their value depends on representative data, validated workflows, human oversight, cybersecurity, and compliance with applicable computerized-system and data-integrity expectations; AI should augment qualified experts rather than replace required scientific judgment.

Regional Insights: Different Regulatory and Manufacturing Priorities

North America emphasizes regulatory compliance, supply assurance, and established quality systems, while Latin America places additional importance on import reliability, registration requirements, and local distribution coordination. Europe is shaped by rigorous quality, environmental, and documentation expectations across interconnected markets. The Middle East increasingly prioritizes dependable access, qualified procurement, and strategic supply continuity; Africa faces infrastructure, logistics, and regulatory-capacity variation that can affect sourcing execution. Asia-Pacific combines substantial pharmaceutical manufacturing capability with diverse national standards, expanding technical capacity, and continued attention to qualification, intellectual-property protection, and resilient cross-border supply chains.

Group Insights: Trade, Regulation, and Strategic Alignment Shape Procurement

ASEAN markets require careful navigation of differing regulatory pathways, logistics networks, and manufacturing capabilities. BRICS participants reflect varied industrial bases and policy environments, making supplier qualification and cross-border coordination important. The European Union benefits from regulatory alignment while retaining country-level operational considerations. G7 markets generally apply advanced compliance, quality, and pharmacovigilance expectations. GCC members emphasize dependable procurement, regional logistics, and healthcare-security priorities, whereas NATO countries may place greater attention on resilience, trusted supply networks, and continuity planning for strategically important medicines.

Country Insights: National Capabilities and Compliance Requirements Differ

Australia combines mature regulatory expectations with geographic supply-chain considerations. Brazil and Mexico require attention to registration, import processes, and local distribution execution. Canada and the United States emphasize robust quality systems, documentation, and supply continuity. China and India offer significant pharmaceutical manufacturing capabilities but require careful assessment of site compliance, inspection readiness, intellectual-property safeguards, and data integrity. France, Germany, Italy, Spain, and the United Kingdom operate within highly demanding European or post-European regulatory environments, with strong focus on quality, traceability, and dependable supply. Japan and South Korea prioritize advanced manufacturing discipline, regulatory precision, and consistent technical documentation. Russia presents additional considerations involving market access, trade restrictions, logistics, and supply-chain risk.

Strategic Actions for Midostaurin API Industry Leaders

Leaders should qualify suppliers through technical audits, impurity and analytical-method reviews, process-validation evidence, change-control records, and documented business-continuity plans. Establishing more than one qualified source, where feasible, can reduce concentration risk, while disciplined inventory policies should reflect lead times, release testing, and regulatory commitments. Organizations should also strengthen technology-transfer governance, align quality and procurement teams early, and maintain country-specific regulatory intelligence. AI adoption should begin with controlled, auditable use cases such as deviation triage, laboratory trending, and documentation support, supported by validation, access controls, and clear accountability.

Research Methodology: Evidence-Based Assessment of the Midostaurin API Landscape

This executive summary applies a qualitative, evidence-based framework focused on the technical, regulatory, operational, and geographic factors relevant to midostaurin API. The assessment organizes insights across required regions, multinational groups, and countries, considering manufacturing capability, quality expectations, market-access conditions, logistics, supply resilience, and digital transformation. It intentionally excludes market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims. Conclusions should be validated against current regulatory notices, official standards, supplier audit findings, technical dossiers, and applicable trade and procurement requirements.

Conclusion: Quality Assurance and Resilient Sourcing Define Competitive Readiness

Midostaurin API strategy is increasingly determined by dependable quality, regulatory preparedness, analytical control, and resilience rather than availability alone. Regional and national differences require tailored execution, while AI offers practical support for process oversight and operational decision-making when governed appropriately. Industry leaders that integrate rigorous supplier qualification, continuity planning, compliant digital tools, and cross-functional governance will be better positioned to manage technical complexity and protect reliable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Midostaurin API Market, by Indication

  • 7.1. Introduction
  • 7.2. Acute Myeloid Leukemia
  • 7.3. Systemic Mastocytosis

8. Midostaurin API Market, by Line Of Therapy

  • 8.1. Introduction
  • 8.2. First Line
  • 8.3. Second Line And Beyond

9. Midostaurin API Market, by Formulation

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
    • 9.3.1. Capsule
    • 9.3.2. Tablet

10. Midostaurin API Market, by Patient Type

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Pediatric

11. Midostaurin API Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Retail Pharmacy

12. Midostaurin API Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Midostaurin API Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Midostaurin API Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Apino Pharma Co., Ltd.
  • 16.2. Aurobindo Pharma Limited
  • 16.3. Chunghwa Chemical Synthesis & Biotech Co., Ltd.
  • 16.4. Cipla Limited
  • 16.5. Concord Biotech Limited
  • 16.6. Dr. Reddy's Laboratories Limited
  • 16.7. Hetero Labs Limited
  • 16.8. Jubilant Life Sciences Limited
  • 16.9. MSN Laboratories Private Limited
  • 16.10. Natco Pharma Limited
  • 16.11. Novartis AG
  • 16.12. Pfizer Inc.
  • 16.13. Procos S.p.A.
  • 16.14. SETV Global Private Limited
  • 16.15. Sun Pharmaceutical Industries Limited
  • 16.16. TAPI Hungary Industries Kft.
  • 16.17. Teva Pharmaceutical Works Private Limited
  • 16.18. Viatris Inc.
  • 16.19. Zaklady Farmaceutyczne Polpharma S.A.
  • 16.20. Zydus Lifesciences Limited

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Midostaurin API Market, Years Considered for the Study
  • FIGURE 2. Global Midostaurin API Market, Research Design
  • FIGURE 3. Global Midostaurin API Market, Research Framework
  • FIGURE 4. Global Midostaurin API Market, Data Triangulation
  • FIGURE 5. Global Midostaurin API Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Midostaurin API Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global Midostaurin API Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Midostaurin API Market Size, by Line Of Therapy, 2025 vs 2032 (%)
  • FIGURE 9. Global Midostaurin API Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Midostaurin API Market Size, by Formulation, 2025 vs 2032 (%)
  • FIGURE 11. Global Midostaurin API Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Midostaurin API Market Size, by Patient Type, 2025 vs 2032 (%)
  • FIGURE 13. Global Midostaurin API Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Midostaurin API Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 15. Global Midostaurin API Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Midostaurin API Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Midostaurin API Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Midostaurin API Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Midostaurin API Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Midostaurin API Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Midostaurin API Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Midostaurin API Market Segmentation & Coverage
  • TABLE 2. Global Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Acute Myeloid Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Acute Myeloid Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Acute Myeloid Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Systemic Mastocytosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Systemic Mastocytosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Systemic Mastocytosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 11. Global First Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global First Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global First Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Second Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Second Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Second Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 18. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 19. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 20. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 21. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 31. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 38. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Midostaurin API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Asia-Pacific Midostaurin API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Asia-Pacific Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 47. Asia-Pacific Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 50. Asia-Pacific Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 51. Asia-Pacific Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 52. North America Midostaurin API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. North America Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 54. North America Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 55. North America Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 56. North America Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 57. North America Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 58. North America Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 59. Latin America Midostaurin API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Latin America Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 61. Latin America Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 62. Latin America Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 63. Latin America Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 64. Latin America Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 65. Latin America Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 66. Europe Midostaurin API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Europe Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 68. Europe Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 69. Europe Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 70. Europe Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 71. Europe Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 72. Europe Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 73. Middle East Midostaurin API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Middle East Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 75. Middle East Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 76. Middle East Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 77. Middle East Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 78. Middle East Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 79. Middle East Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 80. Africa Midostaurin API Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Africa Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 82. Africa Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 83. Africa Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 84. Africa Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 85. Africa Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 86. Africa Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 87. Global Midostaurin API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. ASEAN Midostaurin API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. ASEAN Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 90. ASEAN Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 91. ASEAN Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 92. ASEAN Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 93. ASEAN Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 94. ASEAN Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 95. GCC Midostaurin API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 96. GCC Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 97. GCC Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 98. GCC Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 99. GCC Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 100. GCC Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 101. GCC Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 102. European Union Midostaurin API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. European Union Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 104. European Union Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 105. European Union Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 106. European Union Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 107. European Union Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 108. European Union Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 109. BRICS Midostaurin API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. BRICS Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 111. BRICS Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 112. BRICS Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 113. BRICS Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 114. BRICS Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 115. BRICS Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 116. G7 Midostaurin API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 117. G7 Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 118. G7 Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 119. G7 Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 120. G7 Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 121. G7 Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 122. G7 Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 123. NATO Midostaurin API Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 124. NATO Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 125. NATO Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 126. NATO Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 127. NATO Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 128. NATO Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 129. NATO Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 130. Global Midostaurin API Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 131. United States Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 132. United States Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 133. United States Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 134. United States Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 135. United States Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 136. United States Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 137. United States Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 138. Canada Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 139. Canada Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 140. Canada Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 141. Canada Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 142. Canada Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 143. Canada Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 144. Canada Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 145. Mexico Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 146. Mexico Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 147. Mexico Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 148. Mexico Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 149. Mexico Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 150. Mexico Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 151. Mexico Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 152. Brazil Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 153. Brazil Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 154. Brazil Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 155. Brazil Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 156. Brazil Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 157. Brazil Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 158. Brazil Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 159. United Kingdom Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 160. United Kingdom Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 161. United Kingdom Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 162. United Kingdom Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 163. United Kingdom Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 164. United Kingdom Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 165. United Kingdom Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 166. Germany Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 167. Germany Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 168. Germany Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 169. Germany Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 170. Germany Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 171. Germany Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 172. Germany Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 173. France Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 174. France Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 175. France Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 176. France Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 177. France Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 178. France Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 179. France Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 180. Russia Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 181. Russia Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 182. Russia Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 183. Russia Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 184. Russia Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 185. Russia Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 186. Russia Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 187. Italy Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 188. Italy Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 189. Italy Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 190. Italy Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 191. Italy Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 192. Italy Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 193. Italy Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 194. Spain Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 195. Spain Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 196. Spain Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 197. Spain Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 198. Spain Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 199. Spain Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 200. Spain Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 201. China Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 202. China Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 203. China Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 204. China Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 205. China Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 206. China Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 207. China Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 208. India Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 209. India Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 210. India Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 211. India Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 212. India Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 213. India Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 214. India Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 215. Japan Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 216. Japan Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 217. Japan Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 218. Japan Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 219. Japan Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 220. Japan Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 221. Japan Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 222. Australia Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 223. Australia Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 224. Australia Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 225. Australia Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 226. Australia Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 227. Australia Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 228. Australia Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 229. South Korea Midostaurin API Market Size, 2017-2032 (USD Million)
  • TABLE 230. South Korea Midostaurin API Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 231. South Korea Midostaurin API Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 232. South Korea Midostaurin API Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 233. South Korea Midostaurin API Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 234. South Korea Midostaurin API Market Size, by Patient Type, 2017-2032 (USD Million)
  • TABLE 235. South Korea Midostaurin API Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 236. Global Midostaurin API Market Share, by Key Player, 2025
  • TABLE 237. Global Midostaurin API Market, Key Experts